Introducing the HiPoint® 88 Reperfusion System
The FIRST and ONLY 0.088″ super-bore catheter FDA cleared for direct aspiration in stroke patients.
HiPoint® Reperfusion System
featuring the Monopoint® Approach
The revolutionary HiPoint® Reperfusion System featuring the Monopoint® Approach is the FIRST and ONLY mono-axial platform, powered by the Tenzing® Delivery Catheter, providing a more streamlined approach to stroke intervention. The HiPoint 88 Reperfusion System consists of:
Introducing the HiPoint® 88 Reperfusion System
The FIRST and ONLY 0.088″ super-bore catheter FDA cleared for direct aspiration in stroke patients.
Tenzing 8 Delivery Catheter
Tapered, atraumatic tip is designed to:
Follow the natural flow of blood to seek the primary vessel
Consistently get to your target location
Introducing the HiPoint® 88 Reperfusion System
The FIRST and ONLY 0.088″ super-bore catheter FDA cleared for direct aspiration in stroke patients.
HiPoint 88 Reperfusion Catheter
Rail-based design:
Reduces catheter-within-catheter friction
Enhances operator control
Introducing the HiPoint® 88 Reperfusion System
The FIRST and ONLY 0.088″ super-bore catheter FDA cleared for direct aspiration in stroke patients.
8F Base Camp 2.0 Sheath
Offers optimal support & seamless deliverability to the ICA
Bespoke design engineered for: optimal performance with FreeClimb 88 & HiPoint 88 catheters
One Platform, One Point Of Control
See the Powerful Difference
HiPoint Reperfusion System
featuring the Monopoint Approach
Streamlined, mono-axial set-up
Optimized tools engineered for the challenges of neurovascular anatomy
Designed to work seamlessly together as a custom-built system from puncture to reperfusion
Catheter length allows for versatility across acute ischemic, hemorrhagic, and venous access applications
Traditional System
Multi-axial set-up
Mix-and-match approach, depends on patient anatomy and multiple vendors
Requires multiple catheters that are managed through multiple RHVs
Length constraints that cause set-up “hubbing out”
Superior Deliverability, Redefining Versatility
See the Powerful Approach
Efficient, Effective Intervention
Landmark SUMMIT MAX Trial
FIRST and ONLY randomized controlled trial for aspiration thrombectomy, using the HiPoint Reperfusion Catheter and Tenzing Delivery Catheter for direct aspiration in stroke patients.
96%
successful delivery of HiPoint 88 to the M1*
Powered by Tenzing Delivery
68%
First Pass Effect mTICI≥2c*
84% First Pass Effect mTICI≥2b* Highest recorded First Pass Effect (in Stroke RCTs)
84% First Pass Effect mTICI≥2b* Highest recorded First Pass Effect (in Stroke RCTs)
0%
incidence of sICH*
Excellent safety profile
96%
of the time no adjunctive devices required*
Streamlined setup with reduced stent retriever use
*Data from top 3 enrolling SUMMIT MAX sites
Explore More
“In the management of ICA or proximal M1 occlusions, the 8F Base Camp 2.0 Sheath, HiPoint 88 Reperfusion Catheter and Tenzing 8 Delivery Catheter system stands out as unparalleled, based on my clinical experience. This advanced technology consistently facilitates reliable access to the M1 and achieves complete or near-complete recanalization on the first pass with remarkable consistency.”
Dr. Eytan Raz
NYU Langone Health